NUCLEOLIN and neoplasm: The impact of ApTL/mEGFP might be due to the AS1411 aptamer attachment to nucleolin, which inhibited tumor cell growth by disrupting crucial signaling pathways, making it a potentially safe and specific carrier for targeting tumors.